STAR LAKE SCIENCE(600866)2023-10-30 16:00Financial Performance - The company's operating revenue for Q3 2023 reached CNY 4,462.2 million, representing a 10.14% increase compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was CNY 259.2 million, a significant increase of 186.32% year-on-year[6]. - Basic earnings per share for Q3 2023 were CNY 0.1560, up 97.22% from CNY 0.0525 in the same quarter last year[6]. - The net profit attributable to shareholders for the reporting period reached 2.59 billion RMB, an increase of 186.32% year-on-year, primarily due to increased sales of feed additives and organic fertilizers[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for the reporting period was 667.20 million RMB, reflecting significant year-on-year changes due to the consolidation of Yipin Biological[10]. - The net profit for Q3 2023 is approximately ¥494.91 million, a decrease from ¥993.92 million in Q3 2022, representing a decline of about 50%[20]. - The net profit attributable to shareholders of the parent company is ¥489.40 million, down from ¥500.19 million in the previous year, indicating a decrease of approximately 1.6%[20]. - The total comprehensive income for Q3 2023 is ¥516.30 million, compared to ¥1,015.63 million in Q3 2022, reflecting a decline of about 49%[20]. - Basic and diluted earnings per share for Q3 2023 are both ¥0.2946, down from ¥0.4370 in the same period last year, a decrease of approximately 32.6%[20]. - Net profit attributable to shareholders for the first three quarters was CNY 610,818,485.18, down from CNY 1,200,145,329.24 in the same period last year[19]. Assets and Liabilities - Total assets at the end of Q3 2023 amounted to CNY 13,742.2 million, reflecting a decrease of 14.10% compared to the end of the previous year[6]. - Total current assets as of September 30, 2023, amounted to 4.07 billion RMB, a decrease from 5.96 billion RMB at the end of 2022[16]. - Total assets as of September 30, 2023, were approximately 13.74 billion RMB, down from 15.99 billion RMB at the end of 2022[16]. - Total liabilities decreased to CNY 6,300,699,982.40 from CNY 9,069,255,582.70 year-over-year, indicating improved financial stability[17]. - Total equity increased to CNY 7,441,459,140.94 from CNY 6,929,197,843.84, showing growth in shareholder value[17]. Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 1,726.8 million, down 8.47% from the previous year[6]. - Cash flow from operating activities for the first three quarters of 2023 is ¥1.73 billion, down from ¥1.89 billion in the same period of 2022, a decrease of about 8.5%[22]. - Cash flow from investing activities shows a net outflow of approximately ¥928.77 million, slightly improved from a net outflow of ¥970.26 million in the previous year[23]. - Cash flow from financing activities results in a net outflow of approximately ¥818.22 million, compared to a net outflow of ¥574.01 million in the same period last year, indicating a worsening cash position[23]. - The total cash and cash equivalents at the end of Q3 2023 is approximately ¥828.03 million, down from ¥970.98 million at the end of Q3 2022, a decrease of about 14.6%[23]. - The company received cash from investment recoveries amounting to approximately ¥1.35 billion, significantly higher than ¥604.08 million in the previous year, indicating a strong recovery in investments[22]. - The company paid approximately ¥3.17 billion in debt repayments during the financing activities, slightly up from ¥3.08 billion in the same period last year, reflecting ongoing debt management efforts[23]. Operational Insights - The company reported non-recurring gains of CNY 26.1 million for the current reporting period, compared to CNY 21.9 million for the year-to-date period[9]. - The company has included the financial results of Ningxia Yipin Biotechnology Co., Ltd. in its consolidated financial statements since November 2022, impacting the comparative figures[7]. - The company increased its equity stake in Yipin Biological from 43.78% to 99.22% since November 2022, impacting profit calculations[10]. - Research and development expenses increased to CNY 131,891,666.90, compared to CNY 121,222,773.48 in the previous year, reflecting a focus on innovation[19]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[6]. - The company plans to continue expanding its product lines and market presence, focusing on new product development and technological advancements[10]. - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance revenue growth[19]. Cost Management - Total operating costs increased to CNY 12,113,732,569.61, up 4.5% from CNY 11,587,329,507.21 year-over-year[19]. - Operating profit for the first three quarters of 2023 was CNY 613,605,508.43, a decline from CNY 1,204,932,460.19 in the previous year[19]. - The company reported a decrease in financial expenses to CNY 157,752,844.26 from CNY 206,485,828.02, indicating better cost management[19]. - The company’s cash and cash equivalents position improved, contributing to a stronger liquidity profile[17].